相关实验视频
Updated: Jan 8, 2026

07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
23.9K
局部塞马格卢提德注射治疗因胰岛素高血引起的淋巴功能障碍:叙述性审查提出了淋巴治疗的有希望的代谢前景
1Faculty of Medicine, Novosibirsk State University, Novosibirsk, Russia.
Advanced pharmaceutical bulletin
|December 17, 2025
概括
淋巴 edem 是一种与胰岛素抵抗相关的代谢障碍. 类似葡萄糖类-1受体激活剂 (GLP-1RAs) 通过改善淋巴功能和减少四肢体积来治疗淋巴水具有前景.
科学领域:
- 内分泌学 在内分泌学.
- 血管生物学 血管生物学
- 代谢综合征是代谢综合征的一种.
背景情况:
- 淋巴传统上被视为淋巴阻塞,但越来越多地与代谢功能障碍有关,如胰岛素抵抗和高胰岛素血症.
- 慢性高胰岛素血症会损害淋巴内皮细胞 (LEC) 功能,导致炎症,氧化应激,并通过破坏PI3K/AKT信号传输损害淋巴排水.
- 促炎性细胞因子 (TNF-α,IL-6),高级糖化终产物 (AGEs) 和氧化应激 (ROS) 进一步损害淋巴血管并促进纤维化.
研究的目的:
- 将淋巴重新定义为代谢压力的血管并发症.
- 探索类似葡萄糖-1受体激动剂 (GLP-1RAs) 在治疗淋巴的治疗潜力.
- 提议局部化西马格卢提德作为淋巴的新型治疗策略.
主要方法:
- 这篇叙事综述综合了当前对淋巴的代谢病理生理学的理解.
- 它分析了GLP-1RAs影响胰岛素敏感性,炎症和淋巴功能的机制.
- 研究临床证据,包括最近的病例报告,以支持治疗疗效.
主要成果:
- GLP-1RA增强PI3K/AKT信号传递,改善胰岛素敏感性和减少胰岛素高血压.
- GLP-1RAs激活淋巴血管生成通路 (VEGF-C/VEGFR-3) 并减少氧化应激 (ROS),促进淋巴修复.
- 一个病例报告显示,GLP-1RA治疗的乳腺癌相关淋巴显著减少肢体体积 (10.3%至3.4%),并恢复了淋巴功能.
结论:
- 淋巴水具有重要的代谢基础,使代谢干预至关重要.
- GLP-1RAs代表了淋巴的有前途的治疗类,解决了代谢和血管方面的问题.
- 局部使用像塞马格卢提德这样的药物需要进一步研究以优化淋巴治疗.
相关概念视频
Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
Insulin: Dosing Regimen and Adverse Effects
656
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
656

